April 26, 2023 – Novel Gastric Cancer Drug Under FDA Review Improves Survival

A treatment currently under review by the Food and Drug Administration (FDA) for the treatment of patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma has been shown to improve patients’ overall survival, according to an announcement from the biotechnology company behind the treatment.

Interim results of the RATIONALE 305 study showed that tislelizumab in combination with chemotherapy resulted in a median overall survival time (from the start of the trial until death of any cause) of 17.2 months, compared to 12.6 months for patients who received chemotherapy and a placebo, according to an announcement from drug’s manufacturer, BeiGene.

Read More>